US 12,310,999 B2
Biomarkers for cancer therapeutics
Jennifer Lorraine Gansert, Simi Valley, CA (US); Abraham Antonio Anderson, Sherman Oaks, CA (US); and Kevin Gorski, Novato, CA (US)
Assigned to MERCK SHARP & DOHME CORP., Rahway, NJ (US); and AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 16/499,095
Filed by MERCK SHARP & DOHME CORP., Rahway, NJ (US); and AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Apr. 27, 2018, PCT No. PCT/US2018/029915
§ 371(c)(1), (2) Date Sep. 27, 2019,
PCT Pub. No. WO2018/201028, PCT Pub. Date Nov. 1, 2018.
Claims priority of provisional application 62/491,746, filed on Apr. 28, 2017.
Prior Publication US 2021/0008135 A1, Jan. 14, 2021
Int. Cl. A61K 35/763 (2015.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)
CPC A61K 35/763 (2013.01) [A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/70596 (2013.01); C07K 16/2818 (2013.01); G01N 33/5743 (2013.01)] 18 Claims
 
1. A method of treating a tumor in a subject,
wherein said tumor was non-responsive to previous adjuvant therapy with pembrolizumab or said subject failed to achieve a sustained response to previous adjuvant therapy with pembrolizumab, said method comprising:
administering talimogene laherparepvec to the subject; and
administering pembrolizumab to the subject,
wherein the tumor is melanoma.